OBJECTIVE: There has been recent interest in the use of cognitive enhancing drugs, such as cholinesterase inhibitors, as a possible treatment for executive functioning (EF) deficits in autism spectrum disorder (ASD). The goal of this study was to assess the tolerability, safety, and efficacy of donepezil on EF in a sample of children and adolescents with ASD. METHOD: Thirty-four children and adolescents with ASD (age range 8-17 years; IQ >75) were enrolled in a 10-week, double-blind, placebo-controlled trial of donepezil (doses of 5 and 10 mg), followed by a 10-week open label trial for placebo nonresponders. RESULTS: The effect of donepezil treatment on EF was examined. Despite improvement on a number of EF measures, no statistically significant between-group differences were found (with gains observed for both the placebo and donepezil groups). CONCLUSIONS: The results suggest that short-term treatment with donepezil may have limited impact on cognitive functioning in ASD. Future controlled trials may need to consider a longer treatment period to detect significant gains on EF measures.
RCT Entities:
OBJECTIVE: There has been recent interest in the use of cognitive enhancing drugs, such as cholinesterase inhibitors, as a possible treatment for executive functioning (EF) deficits in autism spectrum disorder (ASD). The goal of this study was to assess the tolerability, safety, and efficacy of donepezil on EF in a sample of children and adolescents with ASD. METHOD: Thirty-four children and adolescents with ASD (age range 8-17 years; IQ >75) were enrolled in a 10-week, double-blind, placebo-controlled trial of donepezil (doses of 5 and 10 mg), followed by a 10-week open label trial for placebo nonresponders. RESULTS: The effect of donepezil treatment on EF was examined. Despite improvement on a number of EF measures, no statistically significant between-group differences were found (with gains observed for both the placebo and donepezil groups). CONCLUSIONS: The results suggest that short-term treatment with donepezil may have limited impact on cognitive functioning in ASD. Future controlled trials may need to consider a longer treatment period to detect significant gains on EF measures.
Authors: Benjamin L Handen; Cynthia R Johnson; Sarah McAuliffe-Bellin; Patricia Jo Murray; Antonio Y Hardan Journal: J Child Adolesc Psychopharmacol Date: 2011-02 Impact factor: 2.576
Authors: Bryan H King; Eric Hollander; Linmarie Sikich; James T McCracken; Lawrence Scahill; Joel D Bregman; Craig L Donnelly; Evdokia Anagnostou; Kimberly Dukes; Lisa Sullivan; Deborah Hirtz; Ann Wagner; Louise Ritz Journal: Arch Gen Psychiatry Date: 2009-06
Authors: Sarah L Logan; Laura Carpenter; R Scott Leslie; Kelly S Hunt; Elizabeth Garrett-Mayer; Jane Charles; Joyce S Nicholas Journal: J Autism Dev Disord Date: 2014-11
Authors: Tatiana M Kazdoba; Prescott T Leach; Mu Yang; Jill L Silverman; Marjorie Solomon; Jacqueline N Crawley Journal: Curr Top Behav Neurosci Date: 2016
Authors: Sharon M Castellino; Janet A Tooze; Lynn Flowers; Debbie F Hill; Kevin P McMullen; Edward G Shaw; Susan K Parsons Journal: Pediatr Blood Cancer Date: 2012-01-11 Impact factor: 3.167
Authors: Gerrit I Van Schalkwyk; Alan S Lewis; Zheala Qayyum; Kourtney Koslosky; Marina R Picciotto; Fred R Volkmar Journal: J Autism Dev Disord Date: 2015-09
Authors: Benjamin L Handen; Cynthia R Johnson; Sarah McAuliffe-Bellin; Patricia Jo Murray; Antonio Y Hardan Journal: J Child Adolesc Psychopharmacol Date: 2011-02 Impact factor: 2.576